Dupilumab (Dupixent (R)) is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.
This real-life French multicenter retrospective cohort study included 241 patients treated during March 2017-April 2018.
The median follow-up time was 4 months (still a very short time, considering that most patients are expected to be on the therapy for longer than 6 months).
Conjunctivitis was reported in 40% patients vs 8-13% in trials, a 4-fold increase. Conjunctivitis was treated with artificial tears and cyclosporine eye drops.
The proportion with eosinophilia (greater than 500 cells/mm3) during follow-up was higher than that at baseline. The previous clinical trials showed transient eosinophilia in less than 2% of patients, the incidence was 5-fold higher in this trial (9.5%).
27 of 241 patients stopped dupilumab because of adverse events (AEs).
This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a much higher frequency of conjunctivitis and eosinophilia.
Atopic dermatitis maintenance (click to enlarge the image).
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019 Jul;81(1):143-151. doi: 10.1016/j.jaad.2019.02.053. Epub 2019 Feb 27.
Dupilumab in the Real World: Beware Adverse Effects. Medscape.
Powered by WPeMatico